<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of this pilot study was to evaluate the feasibility of long-term subcutaneous application of low-dose IL-2 in children with <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> at very high risk of relapse who underwent highly T cell and B cell depleted HLA-identical (MUD) or full haplotype mismatched related hematopoetic stem cell transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>We studied 11 patients with <z:hpo ids='HP_0002488'>acute leukemias</z:hpo> / <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and juvenile myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (active disease and/or second stem cell transplantation, n = 8; â‰¥CR 2, n = 2) and relapsed or progressive Ewing's <z:hpo ids='HP_0100242'>sarcoma</z:hpo> (n = 2) who received prophylactic IL-2 treatment for a high probability of disease recurrence after allo-HSCT </plain></SENT>
<SENT sid="2" pm="."><plain>Toxicities from IL-2 were transient <z:hpo ids='HP_0001945'>fever</z:hpo>, <z:mp ids='MP_0002899'>fatigue</z:mp> and local <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>In one patient GvHD grade III with no clear association to IL-2 administration occurred </plain></SENT>
<SENT sid="4" pm="."><plain>IL-2 administration was started at median day 57 (range 13-154) post-transplant for a mean duration of 28 days (range 15-250) </plain></SENT>
<SENT sid="5" pm="."><plain>IL-2 administration clearly increased NK cell activity </plain></SENT>
<SENT sid="6" pm="."><plain>3 of 11 patients (ALL, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, multifocal Ewings <z:hpo ids='HP_0100242'>sarcoma</z:hpo>) survived with a follow-up of ten years </plain></SENT>
<SENT sid="7" pm="."><plain>In conclusion, long-term low-dose IL-2 subcutaneous application is feasible in children due to a low side effect profile even after HLA mismatched transplantation and may be a strategy to prevent relapse in pediatric <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> with extremely high risk of relapse </plain></SENT>
</text></document>